Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UEA Enterprises Limited is currently managing 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct examiners and 4 distinct art units. This high degree of distribution indicates that the company's current patent applications are being reviewed by a wide variety of individuals and technical groups, which may lead to diverse examination experiences.
KIFLE, BRUCK is identified as the busiest examiner for the portfolio, currently handling 1 pending office action. With 5 pending office actions in total and 5 distinct examiners involved, no single examiner is overseeing more than 1 case. This decentralized structure suggests that each application is receiving an independent review from a different examiner, even within the 4 distinct art units that are currently active.
The presence of 4 distinct art units for only 5 pending office actions highlights the technical breadth of the company's current prosecution efforts. Practitioners should be prepared to navigate the different procedural and substantive preferences of 5 distinct examiners. Maintaining consistency across the Biotechnology & Pharmaceuticals portfolio will require careful monitoring of the 1 pending office action handled by KIFLE, BRUCK and the other four active cases.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (20%) |
| §101 + other | 2 (40%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| MACH, ANDRE | 1 | 44.9% | +51.7% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
| CLOW, LORI A | 1 | 64.2% | +28.5% |
| LEVERETT, MARY CHANG | 1 | 60.2% | +20.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17425384 | NOVEL BIOMARKERS AND DIAGNOSTIC PROFILES FOR PROSTATE CANCER | CLOW, LORI A | 66d overdue |
| 18860392 | BRIDGED BICYCLIC CARBOXYLIC ACIDS FOR TREATING OSTEOSARCOMA AND EWING SARCOMA | KIFLE, BRUCK | — |
| 18696137 | DRY CREAMS AND TOPICAL DELIVERY SYSTEMS | MACH, ANDRE | — |
| 17046829 | CLASSIFICATION AND PROGNOSIS OF PROSTATE CANCER | LEVERETT, MARY CHANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17441849 | PHOTOACTIVE ANTIBODIES | LI, RUIXIANG | 98d overdue |
| 17425384 | NOVEL BIOMARKERS AND DIAGNOSTIC PROFILES FOR PROSTATE CANCER | CLOW, LORI A | 66d overdue |
| 18860392 | BRIDGED BICYCLIC CARBOXYLIC ACIDS FOR TREATING OSTEOSARCOMA AND EWING SARCOMA | KIFLE, BRUCK | — |
| 18696137 | DRY CREAMS AND TOPICAL DELIVERY SYSTEMS | MACH, ANDRE | — |
| 17046829 | CLASSIFICATION AND PROGNOSIS OF PROSTATE CANCER | LEVERETT, MARY CHANG | — |
| Art Unit | Apps |
|---|---|
| 1687 | 2 |
| 1629 | 1 |
| 1615 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18860392 | BRIDGED BICYCLIC CARBOXYLIC ACIDS FOR TREATING OSTEOSARCOMA AND EWING SARCOMA | KIFLE, BRUCK | 1629 | §101§102§103§112 | Non-Final OA | — | Pending | Oct 25, 2024 |
| 18696137 | DRY CREAMS AND TOPICAL DELIVERY SYSTEMS | MACH, ANDRE | 1615 | §103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 17441849 | PHOTOACTIVE ANTIBODIES | LI, RUIXIANG | 1674 | §112 | Final Rejection | 98d overdue | Pending | Sep 22, 2021 |
| 17425384 | NOVEL BIOMARKERS AND DIAGNOSTIC PROFILES FOR PROSTATE CANCER | CLOW, LORI A | 1687 | §101§103§112 | Non-Final OA | 66d overdue | Pending | Jul 23, 2021 |
| 17046829 | CLASSIFICATION AND PROGNOSIS OF PROSTATE CANCER | LEVERETT, MARY CHANG | 1687 | §101 | Final Rejection | — | Pending | Oct 12, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial